key: cord-0801221-nccxlauv
authors: Riccio, Anna; Santopolo, Silvia; Rossi, Antonio; Piacentini, Sara; Rossignol, Jean-Francois; Santoro, M. Gabriella
title: Impairment of SARS-CoV-2 spike-glycoprotein maturation and fusion-activity by nitazoxanide: an effect independent of spike variants emergence
date: 2022-01-03
journal: bioRxiv
DOI: 10.1101/2021.04.12.439201
sha: e5343b74fe943ceeb6e92d712c2fba818c65d3a0
doc_id: 801221
cord_uid: nccxlauv

SARS-CoV-2, the causative agent of COVID-19, has caused an unprecedented global health crisis. The SARS-CoV-2 spike, a surface-anchored trimeric class-I fusion-glycoprotein essential for viral entry, represents a key target for developing vaccines and therapeutics capable of blocking virus invasion. The emergence of SARS-CoV-2 spike-variants that facilitate virus spread and may affect vaccine efficacy highlights the need to identify novel antiviral strategies for COVID-19 therapy. Here we demonstrate that nitazoxanide, an antiprotozoal agent with recognized broad-spectrum antiviral activity, interferes with SARS-CoV-2 spike biogenesis, hampering its maturation at an endoglycosidase H-sensitive stage. Engineering multiple SARS-CoV-2 variant-pseudoviruses and utilizing quantitative cell-cell fusion assays, we show that nitazoxanide-induced spike modifications hinder progeny virion infectivity as well as spike-driven pulmonary cell-cell fusion, a critical feature of COVID-19 pathology. Nitazoxanide, being equally effective against the ancestral SARS-CoV-2 Wuhan-spike and different emerging variants, including the Delta variant of concern, may represent a useful tool in the fight against COVID-19 infections.

Human coronaviruses (HCoV) were discovered in the 1960s and were originally thought to cause only mild upper respiratory tract diseases in immunocompetent hosts, with several strains being responsible for the common cold [1] [2] [3] ; however, public awareness of HCoV has changed considerably since the beginning of this century, with the SARS (Severe Acute Respiratory Syndrome) epidemic in 2002 and the MERS (Middle East Respiratory Syndrome) outbreak in 2012, two zoonotic CoV infections that resulted in mortality rates of approximately 10% and 35%, respectively [4] .

Near the end of 2019 the seventh human coronavirus, phylogenetically in the SARS-CoV clade (lineage B) and therefore named SARS-CoV-2, emerged in China [5] . SARS-CoV-2 turned out to be a far more serious threat to public health than SARS and MERS HCoVs because of its ability to spread more efficiently than its predecessors, making it difficult to contain worldwide, and causing an unprecedented global health crisis, as well as societal and economic disruption. The clinical features of the disease associated with SARS-CoV-2 infection, COVID-19 (coronavirus disease-2019), vary ranging from asymptomatic state to respiratory symptoms that, in a subset of patients, may progress to pneumonia with massive alveolar damage and extreme rise in inflammatory cytokines production that may lead to acute respiratory distress syndrome (ARDS), thrombosis, multi organ dysfunction and death [5, 6] .

SARS-CoV-2 infection is initiated by the binding of the spike (S) glycoprotein to the host receptor, which, similarly to SARS-CoV, is the human angiotensin-converting enzyme 2 (hACE2) [7] [8] [9] . The spike protein, together with the M (membrane) and E (envelope) proteins, is anchored into the viral envelope, decorating the virion surface as a distinctive crown ("corona") ( Fig. 1A) , and is essential for viral entry into target cells [7, 8] .

Similarly to other viral fusion glycoproteins, including influenza hemagglutinin (HA) and parainfluenza fusion (F) proteins, the SARS-CoV-2 spike is a trimeric class-I fusion protein; each monomer is synthesized as a fusogenically-inactive precursor of about 180 kDa containing an Nterminal signal peptide (SP) (Fig. 1B) that primes the nascent polyprotein for import into the endoplasmic reticulum (ER), where the protein is extensively modified with N-linked glycans (each protomer comprises 22 N-linked glycosylation sequons) [10, 11] . The spike protein assembles into an inactive homotrimer, which is endoproteolytically cleaved by cellular proteases giving rise to a metastable complex of two functional subunits: S1 (bulb) containing the receptor-binding domain (RBD) responsible for recognition and attachment to the host hACE2 receptor, and the membrane-anchored S2 (stalk) that contains the fusion machinery (Fig. 1B) . S2 harbors the fusion peptide (FP), a short segment of 15-20 conserved mainly hydrophobic amino acids, which anchors to target membranes and plays an essential role in mediating membrane fusion by disrupting and connecting lipid bilayers of host cells. The FP is followed by two heptapeptide repeat sequences HR1 and HR2, the transmembrane anchor domain (TM), and a short cytoplasmic tail (CT) (Fig. 1B) [9] .

S glycoproteins passing the quality control mechanisms of the ER are transported to the ER/Golgi intermediate compartment (ERGIC), the presumed site of viral budding [12] . Glycosylation plays an essential role in establishing viral spike proteins bioactive conformation and stability, for shaping viral tropism and has effects on virus antigenic properties, receptor binding and fusion activity [10, 13, 14] .

Triggering of SARS-CoV-2 S fusion activity is a multistep process that requires sequential cleavage at distinct sites, including, in addition to the canonical CoV cleavage site at the S1/S2 boundary, an S2' site located immediately upstream of the fusion peptide (Fig. 1B) . In the case of SARS-CoV-2 an unexpected polybasic furin-like cleavage site (FCS), harboring multiple arginine residues, located at the S1/S2 boundary was shown to be processed during S protein biogenesis for S-protein "priming" [7, 15, 16] . Similar cleavage sites have been found in MERS-CoV, but not in other lineage B βCoVs, including SARS-CoV; importantly, the acquisition of similar cleavage sites is associated with increased pathogenicity in other viruses such as avian influenza viruses [17] , and it is suggested to be responsible for SARS-CoV-2 high infectivity and transmissibility [7, 15] .

The SARS-CoV-2 spike glycoprotein is also the primary target of host immune defenses and it is therefore the focus of vaccine development [18, 19] . At present, in parallel with a major vaccination endeavor, widespread whole genome sequencing efforts have allowed researchers to track the spread of different lineages globally, identifying several SARS-CoV-2 spike mutations that, providing fitness advantages, facilitate a rapid spread of the virus, also creating great concern on whether some variants may affect the efficacy of recently developed vaccines [20] [21] [22] [23] .

Therefore, in addition to prophylaxis, antiviral therapeutics remain urgently needed to combat SARS-CoV-2 in the current pandemic.

Nitazoxanide (NTZ), a thiazolide originally developed as an antiprotozoal agent and used in clinical practice for treatment of infectious gastroenteritis [24, 25] , has emerged as a new broad-spectrum antiviral drug [26, 27] . We have previously reported that NTZ and its active circulating-metabolite tizoxanide (TIZ) are effective against different RNA viruses including influenza and parainfluenza viruses, hepatitis C and rotavirus infection in-vitro [28] [29] [30] [31] , as well as in clinical studies [32] [33] [34] .

Interestingly nitazoxanide was also found to be effective against different animal and human coronaviruses, including MERS-CoV [26, 35, 36] and, more recently, SARS-CoV-2 in-vitro [37] [38] [39] and in .

While the molecular mechanism of its broad-spectrum antiviral activity has not been fully elucidated, NTZ was shown to inhibit the replication of influenza and parainfluenza viruses by a novel mechanism, impairing terminal glycosylation and intracellular trafficking of the class-I viral fusion glycoproteins influenza hemagglutinin and paramyxovirus F spike proteins [28, 29] . We therefore explored the possibility that NTZ may also affect SARS-CoV-2 spike maturation, which is critical for SARS-CoV-2 host recognition, penetration and pathogenesis [11] . Herein we report that nitazoxanide interferes with SARS-CoV-2 S-glycoprotein biogenesis, hampering its maturation at an endoglycosidase H (Endo-H)-sensitive stage, and hindering fusion and syncytium-forming ability of the original Wuhan spike, as wells as the Alpha, Beta, Gamma and Delta S-variants in human cells.

Because of its fundamental role in virus infectivity and transmission, the SARS-CoV-2 spike protein structure and function have been extensively studied [7, 10, 43] ; however, little is currently known about the SARS-CoV-2 S (SARS-2 S) biogenesis and maturation pathway.

In order to characterize SARS-CoV-2 S synthesis, oligomerization and furin-mediated cleavage as compared to SARS-CoV and MERS-CoV spike proteins in human lung cells, we have utilized two different expression plasmids, containing the full length SARS-CoV-2 spike gene ORF untagged (VG40589-UT, SARS-2 S) or harboring an antigenic tag (Flag) at the C-terminal (VG40589-CF, SARS-2 S-CF), as well as two plasmids containing the full length human SARS coronavirus (VG40150-CF) and MERS coronavirus (VG40069-CF) spike proteins both harboring a Flag-tag at the C-terminal.

We first asked whether SARS-2 S is robustly expressed in human lung alveolar type II-like epithelial A549 cells, as compared to human HEK293T cells, commonly used for experimentation because of their high transfectability; we also analyzed whether there is evidence for proteolytic processing of the S protein in lung cells, since it has been shown that SARS-2 S is cleaved by host cell proteases at the S1/S2 cleavage site in HEK293T cells [8] .

Immunoblot analysis of A549 cells expressing the untagged SARS-2 S protein revealed a band with a molecular weight of 180 kDa expected for unprocessed S protein (S0) (Fig. 1C) ; a band with a size expected for the spike S1 subunit (∼110 kDa) [44] was also observed at all times tested. In addition to A549 cells, similar results were obtained in human normal lung MRC-5 fibroblasts (Fig.   1D ). In A549 cells expressing the SARS-2 S protein with a C-terminal antigenic tag, in addition to the unprocessed S0, a band with a size expected for the S2 subunit (∼90 kDa) [45] was also observed when anti-Flag antibodies were utilized (Fig. 1E) . These results suggest efficient proteolytic processing of SARS-2 S protein during biogenesis in human pulmonary cells, in keeping with the presence of several arginine residues at the S1/S2 cleavage site.

To confirm the involvement of furin in S protein processing during biogenesis, we analyzed whether the furin irreversible inhibitor decanoyl-RVKR-CMK (RVKR) blocks SARS-2 spike protein processing in our model. As shown in Fig. 1F ,G,H, RVKR inhibited SARS-2 S processing in a concentration-dependent manner, confirming that the SARS-CoV-2 spike cleavage is mediated by furin; RVKR also inhibited the processing of MERS S protein, which is known to depend on furin [46] , while it had no effect on SARS S protein expression (Fig. 1I) , as expected.

It is interesting to note that inhibition of furin activity by RVKR did not prevent SARS-2 spike trimerization (Fig. 1H) , indicating that S1/S2 cleavage is not required for oligomerization in lung cells.

We have previously shown that nitazoxanide (NTZ, Fig. 2A ) inhibits the replication of influenza and parainfluenza viruses by impairing terminal glycosylation and intracellular trafficking of the class-I viral fusion glycoproteins influenza hemagglutinin and paramyxovirus fusion spike proteins [28, 29] . To investigate whether NTZ may also affect SARS-CoV-2 spike glycoprotein expression, human lung (A549 and MRC-5), colon (HCT116), liver (Huh7) and kidney (HEK293T) cells were transiently transfected with the SARS-2 S or SARS-2 S-CF plasmids and, after 4h, were treated with different concentrations of NTZ (Fig. 2B ). As shown in Fig. 2C and Fig. S1A , NTZ did not inhibit S protein expression and did not interfere with the S1/S2 cleavage; however, treatment with NTZ at concentrations higher than 0.1 µg/ml caused an evident alteration in the molecular mass of both the S0 precursor and the S1/S2 subunits. This effect persisted for at least 24h ( Fig. S1B ) with no change in cell viability, as shown by MTT assay (NTZ LD 50 >50 µg/ml). Interestingly NTZ treatment provoked a similar alteration of SARS-CoV and MERS-CoV spike glycoproteins exogenously expressed in A549 cells (Fig. 2D) . Notably, the NTZ-mediated spike alteration was not affected by the presence of single and/or multiple mutations in the S protein, including the aspartic acid-to-glycine substitution at position 614 (D614G) (Fig. 2E) , an S-protein globallypredominant mutation that was found to promote SARS-CoV-2 transmission in humans [47] , and the N501Y, E484K and K417N mutations (Fig. S2A) (VOC) spike-glycoproteins exogenously expressed in A549 cells (Fig. 2F ). Finally, it should be noted that, in addition to human cells, nitazoxanide was found to affect SARS-CoV-2 spike biogenesis also in monkey (Vero E6), rodent (murine L929 fibroblasts) and bat lung epithelial cells Tb-1 Lu cells ( Fig. S1C-E) , indicating a general effect on mammalian cells.

The NTZ-induced alteration in the S glycoprotein electrophoretic mobility pattern was mimicked by the NTZ active metabolite, tizoxanide (Fig. S3A ), but not by other antiviral drugs, including chloroquine (10 µM), ribavirin (7.5 µM) and remdesivir (7.5 µM) (Fig. 2G ).

Whereas the antiviral activity of nitazoxanide against SARS-CoV-2 replication has been reported To investigate whether NTZ treatment affects SARS-CoV-2 S protein stability, A549 cells were transfected with the SARS-2 S construct and treated with NTZ (2.5 µg/ml) for 16h, at which time protein synthesis was arrested by adding cycloheximide (100 µg/ml). At different times after cycloheximide treatment S protein levels were determined in whole-cell extracts by Western blot and quantitated by scanning densitometry. The results, shown in Fig. 3A , indicate that S protein degradation rate (with a half-life of 7.5h) is not significantly affected by the thiazolide. Comparable levels of S-protein were also detected by confocal microscopy in A549 cells untreated or treated with nitazoxanide (5 µg/ml) for 16h (Fig. 3B) . Notably, nitazoxanide did not prevent the formation of SARS-2 spike dimers and trimers, which, however, were characterized by an evident alteration in electrophoretic mobility, reflecting the monomer modification (Fig. 3C ).

Although it is known that glycosylation plays an essential role in establishing coronavirus spike proteins bioactive conformation, stability, tropism and fusion activity [10, 13, 14] , presently there is little information on the effect of glycosylation inhibitors on SARS-CoV-2 spike biogenesis. The thiazolide-induced SARS-2 spike alteration was then compared to the effect of the N-glycosylation inhibitor tunicamycin. Interestingly, non-glycosylated spike protein was not detected in the soluble fraction of tunicamycin-treated cells (Fig. S4A, top) , an effect that could not be rescued by treatment with the proteasome inhibitor bortezomib [48] , suggesting that non-glycosylated proteins are not promptly degraded via ERAD (ER-associated degradation), a sophisticated process for ERto-cytosol dislocation and ubiquitin/proteasome-mediated degradation of target-proteins [49] . In fact, immunomicroscopy studies revealed the formation of large S protein aggregates in tunicamycin-treated cells (Fig. S4B ); in addition, the presence of a low-molecular weight band, corresponding to the non-glycosylated spike protein (∼130 kDa), was detected in the insoluble fractions of tunicamycin-treated cell lysates (Fig. S4A, bottom) . Similar results were previously reported for the spike protein of transmissible gastroenteritis virus (TGEV) CoV [50] .

Glycosylation of coronavirus S proteins, like other cell surface glycoproteins, is initiated in the endoplasmic reticulum, adding the "high mannose" oligosaccharides; the mannose-rich sugar component is processed in the Golgi apparatus, and terminal glycosylation occurs in the trans cisternae of the Golgi apparatus [51] .

We have previously shown that nitazoxanide blocks the maturation of the influenza virus hemagglutinin at a stage preceding resistance to digestion by endoglycosidase H (Endo-H), an enzyme that removes N-linked carbohydrate chains that have not been terminally glycosylated ( Fig.   3E ) [52] , thus impairing HA intracellular trafficking [28] . To obtain insights on the effect of NTZ on SARS-2 S maturation, we therefore investigated whether nitazoxanide could affect S protein terminal glycosylation. SARS-CoV-2 S protein aliquots from NTZ-treated or control cells were subjected to digestion with Endo-H or with PNGase-F, an enzyme that removes all N-glycans [53] , up to 6 h after cycloheximide treatment and then analyzed by immunoblot. As expected, S proteins from both untreated and NTZ-treated cells were sensitive to PNGase-F digestion (Fig. 3F ). On the other hand, a fraction (approximately 42-43% between 1 and 6h after cycloheximide treatment) of the SARS-CoV-2 S protein was found to be terminally glycosylated becoming Endo-H-resistant in control cells under the conditions described; notably, S protein from NTZ-treated cells remained instead sensitive to digestion with the glycosidase up to 22h after synthesis (Fig. 3F ). Because acquisition of Endo-H resistance is a marker for transport into the cis and middle Golgi compartments [52] , these results indicate that nitazoxanide, as in the case of influenza HA [28] , may impair S protein trafficking between the ER and the Golgi complex. Of note, treatment with nitazoxanide did not significantly alter the expression of calnexin or other ER proteins, including calreticulin, ERp57, ERp72 and the ER-stress regulated protein GRP78, suggesting that the drug is not triggering the host ER-stress response (Fig. 3D ). It should also be noted that, at the effective concentration, nitazoxanide does not alter the expression of the other SARS-CoV-2 structural proteins N, M and E when expressed alone ( Fig. S5A ) or in combination (Fig. S5B ). It is important to note that the presence of large amounts of the nucleocapsid, envelope and in particular the membrane protein, which is known to interact with the S glycoprotein [54] , did not prevent the NTZ-induced spike alteration (Fig. S5B) .

Finally, the thiazolide-induced SARS-2 spike alteration was also compared to the effect of different glycoprotein maturation inhibitors, including the α-glucosidases inhibitor castanospermine, the ER-Golgi protein trafficking inhibitor brefeldin A, and the mannosidase-I inhibitors deoxymannojirimicin (DMJ) and kifunensine, which was recently shown to alter SARS-CoV-2 spike processing and infectivity [55] . As shown in Fig. S4C , neither α-glucosidases nor mannosidase inhibitors caused an alteration in molecular mass comparable to nitazoxanide, suggesting a different activity of the drug. Interestingly, brefeldin A treatment, differently from nitazoxanide, inhibited S protein cleavage (Fig. S4C ).

These results indicate that, as in the case of influenza HA and parainfluenza fusion proteins, nitazoxanide treatment results in hampering SARS-CoV-2 spike maturation.

Since biochemical assays using purified viral components do not provide insights on the S protein function as it occurs on the virion membrane, we engineered pseudotyped retroviral (Murine Leukemia Virus, MLV) as well as third-generation lentiviral (pLV) particles to express the fulllength SARS-CoV-2 S protein together with a luciferase (LUC) or green fluorescent protein (GFP)

reporter to monitor infection (Fig. 4A ).

SARS-CoV-2 S-pseudotyped particles were generated in producer HEK293T cells treated with different concentrations of nitazoxanide or control diluent for 48h and then used to infect different types of cells, including monkey Vero E6 cells, that are commonly used in the study of SARS-CoV-2 entry due to their high susceptibility to infection, as well as human airway epithelial Calu-3 cells and intestinal epithelial Caco-2 cells, which both express the ACE2 receptor on their apical surface [56] ; in addition, as HEK293T cells were not susceptible to infection by SARS-CoV-2 Spseudotyped viruses [45] , we generated HEK293T cells stably expressing the human ACE2 receptor (293T hACE2 cells) for these studies.

As shown in Fig 

Besides fusion mediated by virions, SARS-CoV-2 S proteins present at the plasma membrane, contrary to the S protein of the related coronavirus SARS-CoV [57] , can trigger receptor-dependent formation of syncytia, which have been observed not only in cell cultures but also in tissues from individuals infected with SARS-CoV-2 [15, 58] .

To address the question whether the alteration in SARS-CoV-2 S glycoprotein maturation observed in nitazoxanide treated cells may affect cell-cell fusion and syncytia formation, we utilized two different approaches.

In the first approach monkey Vero E6 cells and human Huh7 cells, both naturally expressing ACE2 receptors on the membrane surface, transiently transfected with the Flag-tagged SARS-CoV-2 or SARS-CoV (Huh7) spike plasmids were treated with nitazoxanide or vehicle, and processed for immunofluorescence microscopy using an anti-Flag antibody to visualize syncytia formation after 36h. Consistently with previous reports [57] , In a second type of approach, we investigated whether the drug may prevent cell-cell fusion between different cell types. HEK293T cells were co-transfected with plasmids encoding the Flagtagged SARS-CoV-2 S glycoprotein and GFP and, after 4h, treated with nitazoxanide or vehicle ( Fig. 5C ). At 40h post transfection cells were detached and overlaid on an 80% confluent monolayer of target Vero E6 and Huh7 cells at a ratio of approximately one S-expressing cell to three receptor-expressing cells. After 4h, co-cultures were processed for fluorescence microscopy to visualize syncytia formation, and the extent of cell-cell fusion was determined as described [59] .

As shown in Fig. 5D ,E, also in this case treatment with nitazoxanide markedly decreased the number and size of syncytia in both Vero E6 cells (Fig. 5D ) and Huh7 cells (Fig. 5E ), confirming that nitazoxanide may prevent SARS-CoV-2 S-mediated fusion between different types of cells.

Formation of syncytia by pneumocytes expressing SARS-CoV-2 RNA and S proteins was observed post-mortem in lung tissues of COVID-19-infected patients [58] . We therefore investigated whether nitazoxanide treatment may prevent SARS-CoV-2 S-mediated fusion in human lung alveolar type II-like A549 cells. As these cells are known to possess low levels of ACE2 [8] , we generated A549 cells stably expressing the human ACE2 receptor (A549 hACE2 cells) for these studies. 6A ). Similar results were obtained when A549 hACE2 cells were used as target cells in the cell-cell fusion co-culture model, using HEK293T cells co-transfected with plasmids encoding the Flagtagged SARS-CoV-2 S-glycoprotein and a GFP reporter as donor cells (Fig. 6B ). NTZ-induced inhibition of cell-cell fusion was dose-dependent, with a >90% suppression of syncytia formation at the concentration of 10 µg/ml (Fig. S8A ).

It is known that the SARS-CoV-2 E and M proteins regulate processing and intracellular trafficking of the S glycoprotein, interfering with syncytia formation [54, 60, 61] ; we therefore investigated whether co-expression of the structural proteins N, M and E with the spike glycoprotein would affect the ability of the drug to inhibit S-mediated cell-cell fusion. As shown in Fig. S5C , the presence of the N, M and E proteins did not prevent cell-cell fusion and did not hinder the ability of nitazoxanide to suppress syncytia formation in lung cells.

These results confirm that SARS-CoV-2 S-protein possesses high fusogenic activity and is able to trigger large syncytia formation in human lung cells, and indicate that the alteration in SARS-CoV-2 S glycoprotein maturation observed in nitazoxanide-treated cells impairs spike-driven cell-cell fusion and syncytia formation.

Although coronaviruses are thought to mutate at a slower rate than most RNA viruses due to the presence of a unique viral proofreading machinery [1, 62] , CoVs can also undergo recombination events [63] . A meta-analysis of genomes of SARS-CoV-2 strains found several mutations within the virion spikes circulating in a considerable percentage of the analyzed populations [21] [22] [23] . The most common mutation, now found in most of the global population, is an aspartic acid-to-glycine substitution at position 614 (D614G) in the S1 subunit of the spike protein [47] . The D614G S mutation has been shown to promote SARS-CoV-2 transmission in humans and to enhance functional S-protein incorporation into SARS-CoV-2 virus-like particles and pseudovirus particles, increasing pseudovirions infectivity [64] .

To investigate whether nitazoxanide treatment was equally effective in inhibiting the infectivity of the SARS-CoV-2 D614G spike variant, we utilized the pCAGGS-SARS2-S-D614 S (wild type, SARS-2 D614) plasmid and the pCAGGS-SARS2-S-G614 S plasmid carrying the D614G mutation (SARS-2 G614), both containing a C-terminal antigenic Flag-tag, to engineer pseudotyped lentiviral particles expressing the full-length SARS-CoV-2 S protein together with a LUC reporter.

SARS-CoV-2 D614G S-pseudotyped particles were generated in producer HEK293T cells treated with nitazoxanide (2.5 µg/ml) for 48h and then used to infect 293T hACE2 cells and intestinal epithelial Caco-2 hACE2 cells.

As shown in Fig. 7A , nitazoxanide treatment caused the expected SARS-CoV-2 D614G spike alteration in HEK293T producer cells and resulted in a dramatic decrease of SARS-CoV-2 D614G

S pseudotyped particles infectivity in both 293T hACE2 and Caco-2 hACE2 cells (Fig. 7B ).

Next, human lung A549 hACE2 cells were transfected with the Flag-tagged SARS-CoV-2 D614 or G614 spike plasmids, treated with nitazoxanide or vehicle, and processed for immunofIuorescence microscopy using an anti-Flag antibody to visualize syncytia formation after 36h. As shown in Fig.   7C , expression of the SARS-CoV-2 G6k14 S glycoprotein was markedly more effective in causing the formation of large multi-nucleated syncytia in lung cells as compared to the wild-type protein.

Treatment with nitazoxanide was found to significantly decrease the number and size of syncytia caused by the SARS-CoV-2 G614 spike variant (Fig. 7C ).

Similar results were obtained when A549 hACE2 cells were used as target cells in the fusion coculture model described above, using HEK293T cells co-transfected with plasmids encoding the SARS-CoV-2 S D614 or G614 spike variant together with a GFP reporter as donor cells (Fig. 7D ).

In addition to the G614 spike variant, nitazoxanide was found to significantly decrease the number and size of syncytia caused by SARS-CoV-2 spike proteins carrying single or multiple mutations including the N501Y, E484K and K417N substitutions (Fig. S2B ,C) that, as indicated above, have Next, we investigated the ability of nitazoxanide to prevent syncytia formation induced by the Alpha, Beta, Gamma and Delta variants. HEK293T cells were co-transfected with the plasmids of interest and GFP and, after 4h, treated with nitazoxanide or vehicle. At 40h post transfection cells were overlaid on target A549 hACE2 cells monolayers, and processed for fluorescence microscopy to visualize syncytia formation, as described above. As shown in Fig. 8E -I, all spike variants were able to cause cell-cell fusion, and treatment with nitazoxanide markedly decreased the number and size of syncytia in lung cells. As shown above, NTZ-induced inhibition of syncytia formation was dose-dependent (Fig. S8 ).

Altogether these results indicate that nitazoxanide is effective in inhibiting cell-cell fusion and syncytia formation mediated by different SARS-CoV-2 spike variants and in different types of cells. While the molecular mechanism of its broad-spectrum antiviral activity has not been fully elucidated, nitazoxanide acts through a cell-mediated mechanism [26, 27] and, in the case of influenza and parainfluenza viruses, it was shown to impair terminal glycosylation and intracellular trafficking of the class-I viral fusion glycoproteins influenza hemagglutinin and paramyxovirus fusion spike proteins [28, 29] . This effect has been previously associated to the drug-mediated inhibition of ERp57, an ER-resident glycoprotein-specific thiol-oxidoreductase which is essential for correct disulfide-bond architecture of selected viral proteins [29] .

We now show that nitazoxanide selectively interferes with SARS-CoV-2 S-glycoprotein Since its emergence, the ancestral Wuhan strain has evolved rapidly, originating several variants harboring multiple mutations, including mutations in the spike protein, which may result in the ability to evade part of the neutralizing antibody response [21] [22] [23] . We found that nitazoxanide ability to interfere with the S-glycoprotein maturation is independent of the spike variants, being equally effective against the original Wuhan-spike as well as the Alpha, Beta, Gamma and Delta spike-variants in human cells. This is in line with the cell-mediated mechanism of action previously reported for NTZ [26] [27] [28] [29] , and represents an advantage as compared to virus-targeted drugs, considering the continuous emergence of SARS-CoV-2 variants and the CoV ability to undergo recombination events [63] . Interestingly, NTZ was also found to interfere with the maturation of the spike proteins of the human alpha coronavirus 229E and beta coronavirus OC43, causing a remarkable decrease in infectious progeny production in human cells (Piacentini S. et al., manuscript in preparation), and confirming a general effect of the drug against diverse human coronaviruses.

The ability of SARS-CoV-2 S protein to mediate fusion between the viral particle and the cellular membranes during virus entry has been largely studied and documented; however, there is recent evidence that the spike protein is also responsible for fusion of infected cells with neighboring uninfected cells [59, 68] . This process, known as 'fusion from within', is mediated by newly synthesized S protein reaching the cell surface, fusing with receptor-positive adjacent cells, and causing the formation of giant multinucleated cells (syncytia). Cell-cell fusion is used by different viruses, including the Pneumovirus RSV (Respiratory Syncytial virus), the measles virus (MV) [69] and the human immunodeficiency virus (HIV) [70] , to spread in a particle-independent way and promoting immune evasion [71] .

Utilizing two different quantitative assays relying on the biogenesis of expressed S protein, we now confirm that the SARS-CoV-2 Wuhan-spike as well as the Alpha, Beta, Gamma and Delta spikevariants possess remarkable cell-cell membrane fusion activity, causing syncytia formation in ACE2-expressing cells, and demonstrate that nitazoxanide is effective in inhibiting syncytia formation mediated by the different spike-variants in different types of cells.

Syncytia formation has been linked to pathological consequence detectable in various tissues such as lung and brain for MV [72] or lymphoid tissues for HIV [70] . In the case of SARS-CoV-2 infection, syncytia formation has been recently described as an hallmark of advanced lung pathology in patients affected with COVID-19 in an occurrence not seen in other lung infections before [58, [73] [74] [75] [76] . In particular, fused pneumocytes expressing SARS-CoV-2 RNA and S proteins were observed post-mortem in lung tissues of 20 out of 41 COVID-19-infected patients, indicating that productive infection leads to syncytia formation [58] . Notably SARS-CoV-2 S-mediated syncytia were suggested to increase viral pathogenicity by destabilizing airway epithelia and creating lesions that may be difficult to repair [75] . Interestingly, it has also been recently shown that, whereas neutralizing antibodies and sera from convalescent patients inhibited SARS-CoV-2 particle-cell fusion with high efficiency, cell-cell fusion was only moderately inhibited, suggesting that syncytia formation during COVID-19 may not be effectively prevented by antibodies [68] .

The results described herein suggest that, together with virus-targeting drugs, the host-directed broad-spectrum antiviral drug nitazoxanide, by hampering the spike protein maturation and fusion activity, may represent a readily-available useful tool in the fight against COVID-19 infections, inhibiting SARS-CoV-2 replication and preventing spike-driven syncytia formation.

Human alveolar type II-like epithelial A549 cells, inhibitors) by sonication on ice, using an ultrasonic UP50H processor (Hielscher) (40% amplitude, pulse mode: 6×10 sec, 15 sec pauses) [79] .

For Western blot analysis, cell extracts (20 µg/sample) were separated by SDS-PAGE under nonreducing conditions and blotted to a nitrocellulose membrane. Membranes were incubated with the selected antibodies, followed by incubation with peroxidase-labeled anti-rabbit or anti-mouse IgG.

Primary and secondary antibodies used are listed in Supplementary Table 1. For endoglycosidase digestion experiments, samples containing the same amount of protein (50 µg/sample) were processed for endoglycosidase-H (Endo-H, NEB) digestion using 5 milliunits

Endo-H for 16h at 37°C, or for peptide N-glycosidase F (PNGase-F, NEB) digestion using 500 units PNGase-F for 1,5h at 37°C, according to the manufacturer's protocol [28] . Samples were separated by SDS-PAGE under reducing conditions and blotted as described above. Quantitative evaluation of proteins was determined as described [80] [81] [82] . All results shown are representative of at least three independent experiments.

A549 cells transfected with Flag-tagged SARS-CoV-2 spike or empty vector were grown in 8-well chamber slides (Lab-Tek II) and, after 4h, were treated with NTZ, TM or vehicle for 16h. Cells were fixed, permeabilized and processed for immunofluorescence as described [83] using anti-Flag antibodies, followed by decoration with Alexa Fluor 488-or 555-conjugated antibodies (Molecular Probes, Invitrogen). Nuclei were stained with Hoechst 33342 (Molecular Probes, Invitrogen).

Images were captured using a ZEISS Axio Observer Inverted Microscope and analyzed using ZEN 

Two different protocols were used for visualization of syncytia. In the first protocol, Vero E6, Huh7, A549 and A549 hACE2 cells grown in 8-well chamber slides were transfected with Flagtagged SARS-CoV-2 (SARS-2 S-CF wild type or mutated, pCAGGS-SARS2-S-D614, pCAGGS-SARS2-S-G614) or SARS-CoV spike plasmids or empty vector and, after 4h, were treated with NTZ or vehicle. After 36h, cells were processed for immunfluorescence as described above using an anti-Flag antibody. Nuclei were stained with Hoechst. Syncytia images were captured using a ZEISS Axio Observer inverted microscope and analyzed using ZEN 3.1 (blue edition) software. For syncytia formation quantification, the percentage of cells involved in syncytia formation was determined by counting the number of cells containing 3 or more nuclei, compared with the number of total nuclei in transfected cells in the same sample [57] . At least 1.000 nuclei were counted for each sample.

In the donor-target cell fusion assay, 293T cells were co-transfected with plasmids encoding Flag- [45] . After 4h, nuclei were stained with Hoechst. Transmission and fluorescence images were taken using a ZEISS Axio Observer inverted microscope. To measure the extent of cell-cell fusion, the GFP area was delimited, measured using ImageJ software [59] , divided by the total cell area and expressed as percentage relative to control.

Images shown in all figures are representative of at least five random fields (scale-bars are indicated). All experiments were done in duplicate and repeated at least three times. All experiments were performed in triplicates, and repeated at least three times.

To inhibition is derived from the average of the untreated infected control). Cell viability was determined by MTT assay [29] . Cytotoxicity values were normalized to the internal control (untreated cells, 100% viability). Tizoxanide antiviral activity assays against SARS-CoV-2 were performed by Virology Research Services Ltd (UK).

Statistical analysis was performed using the Student's t-test for unpaired data or one-way ANOVA 

Origin and evolution of pathogenic coronaviruses

The architecture of SARS-CoV-2 transcriptome

Human Coronavirus: host-pathogen interaction

SARS and MERS: recent insights into emerging coronaviruses

Characteristics of SARS-CoV-2 and COVID-19

Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Distinct conformational states of SARS-CoV-2 spike protein

The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy

The glycosylation in SARS-CoV-2 and its receptor ACE2

Role of the early secretory pathway in SARS-CoV-2 infection

Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens

Folding of viral envelope glycoproteins in the endoplasmic reticulum

A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells

Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site

Influenza: lessons from past pandemics, warnings from current incidents

SARS-CoV-2 variants and vaccines

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

The way of SARS-CoV-2 vaccine development: success and challenges

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

COVID-19 Genomics UK (COG-UK) Consortium et al (2021) SARS-CoV-2 variants, spike mutations and immune escape

Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide

Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species

Nitazoxanide: a first-in-class broad-spectrum antiviral agent

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level

Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

Thiazolides, a new class of antiviral agents effective against

Characterization of the SARS-CoV-2 spike in an early prefusion conformation

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune crossreactivity with SARS-CoV

Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein

Fontes-Garfias CR et al (2020) Spike mutation D614G alters SARS-CoV-2 fitness

Proteasome inhibitors in cancer therapy

Pathogenic hijacking of ER-associated degradation: is ERAD flexible?

Carbohydrate-induced conformational changes strongly modulate the antigenicity of coronavirus TGEV glycoproteins S and M

Glycosylation-directed quality control of protein folding

Oligosaccharides in the stem region maintain the influenza virus hemagglutinin in the metastable form required for fusion activity

Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors

The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles

Inhibition of SARS-CoV-2 viral entry upon blocking N-and O-glycan elaboration

Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology

Syncytia formation by SARS-CoV-2-infected cells

SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles

Betacoronavirus assembly: clues and perspectives for elucidating SARS-CoV-2 particle formation and egress

Coronavirus RNA proofreading: molecular basis and therapeutic targeting

Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

Seasonal coronavirus protective immunity is short-lasting

Remdesivir: from Ebola to COVID-19

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusionfrom-without

Measles virus persistence and its consequences

They might me giants: does syncytium formation sink or spread HIV infection?

Avoiding the void: cell-to-cell spread of human viruses

Measles encephalitis: towards new therapeutics. Viruses

Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Sequences in the cytoplasmic tail of SARS-CoV-2 spike facilitate expression at the cell surface and syncytia formation

SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Murine leukemia virus (MLV)-based coronavirus spikepseudotyped particle production and infection

Human NF-κB repressing factor acts as a stress-regulated switch for ribosomal RNA processing and nucleolar homeostasis surveillance

Prostaglandin A inhibits the replication of vesicular stomatitis virus: effect on virus glycoprotein

Inhibition of virus protein glycosylation as the mechanism of the antiviral action of prostaglandin A in Sendai virus-infected cells

The zinc-finger AN1-type domain 2a gene acts as a regulator of cell survival in human melanoma: role of E3-ligase cIAP2

The proteostasis guardian HSF1 directs the transcription of its paralog and interactor HSF2 during proteasome dysfunction

A versatile viral system for expression and depletion of proteins in mammalian cells

Cell entry mechanisms of SARS-CoV-2

CoV-2 spike glycoproteins, and the putative furin cleavage site (RRAR residues in the box) in SARS-CoV-2 are shown. GenBank accession numbers are AFR58740.1 for SARS-CoV S and QHD43416.1 for SARS-CoV-2 S [85]. (C,D) Detection of SARS-CoV-2 S protein (α-spike) levels by immunoblot (IB) in whole cell extracts (WCE) from human lung

SARS-2 S) or empty vector (Mock) at different times (C) or at 20h (D) after transfection. (E) A549 cells were transiently transfected with the C-terminal Flag-tagged SARS-CoV-2 spike construct

CF) or empty vector and, at different times, WCE were analyzed for S protein levels by IB using anti-spike or anti-Flag antibodies. (F,G) Levels of S protein determined by IB using anti-spike or anti-Flag antibodies in WCE from A549 cells

Merge images are shown. Scale bar, 20 µm. Data from a representative experiment of three with similar results are shown. (C) Gel electrophoresis (4% polyacrylamide) of WCE from A549 cells transfected with SARS-2 S construct or empty vector and treated with different concentrations of NTZ for 16h. The different forms (trimers, dimers and monomers) of the S protein were visualized by IB with anti-spike antibodies. The slower-and faster-migrating forms of S protein are identified by asterisks and red arrowheads respectively. (D) IB of S protein (α-spike), calreticulin (CRT), calnexin (CNX), GRP78 (anti-KDEL), ERp72 and ERp57 in WCE from A549 cells transfected with the SARS-2 S construct or empty vector for 4h and treated with 2.5 µg/ml NTZ (+) or vehicle (-) for different times

N-acetylglucosamine (GlcNAc, green squares) and asparagine (Asn, yellow triangle) residues are shown. (F) A549 cells transfected with C-Flag tagged SARS-CoV-2 spike (SARS-2 S-CF) construct or empty vector (Mock) for 4h were treated with NTZ (2.5 µg/ml) or vehicle. After 16h, CHX (100 µg/mL) was added (time 0); at different times after CHX addition proteins were digested with Endo-H or PNGase-F (+) or left untreated (-) and processed for IB analysis using anti-Flag antibodies and quantitated by scanning densitometry

PNGaseF-cleaved faster-migrating S and S2 forms are indicated by white arrowheads. The percentage of Endo-H-resistant (Endo-H R) S protein in the different samples is indicated. Black arrows indicate bands corresponding to uncleaved S protein (S0)

Nitazoxanide treatment inhibits SARS-CoV-2 S pseudovirus infectivity

SARS-CoV-2 spike pseudotyped lentiviral (LV) or retroviral (MLV) particles carrying a reporter gene are produced in the presence of NTZ or vehicle (C) and used to infect different types of human cells, which will express LUC or GFP upon infection

CoV-2 spike pseudotyped-LUC MLV particles (C) (see 'Materials and Methods'), were treated with (A) A549 cells stably expressing human ACE2 (A549 hACE2) or wild-type (WT) were transiently transfected with the SARS-2 S-CF construct for 4h and treated with NTZ (5 µg/ml) or vehicle (Control) for 36h

Scale bar, 200 µm (zoom, 200 µm). hACE2 protein levels in A549 WT (-) and A549 in the same sample (right panel). Data represent the means±SD of 5 fields from three biological replicates. *P<0.05; ANOVA. (B) HEK293T cells co-transfected with plasmids encoding SARS-CoV-2 S and GFP for 4h and treated with NTZ (5 µg/ml) or vehicle (Control) for 36h were overlaid on A549 hACE2 cell monolayers. After 4h, cell-cell fusion was assessed by fluorescence microscopy

Cell-cell fusion was determined and expressed as percentage relative to control

At 48h post-transfection, pseudovirus-containing supernatants were collected for infection of 293T hACE2 or Caco-2 hACE2 cells. SARS-CoV-2 S expression was detected in WCE of HEK293T pseudovirus-producing cells by IB using anti-spike antibodies (A). 293T hACE2 or Caco-2 hACE2 cells were infected with SARS-CoV-2 spike-pseudotyped LV-particles obtained as described above and pseudovirus entry was analyzed by measuring LUC activities 72h postinfection (B). Data are expressed as percent of relative untreated controls. Error bars indicate means±SD. **P<0.01; Student's t-test. (C) A549 hACE2 cells were transiently transfected with the C-Flag tagged SARS-CoV-2 D614 or G614 spike constructs for 4h and treated with NTZ (5 µg/ml) or vehicle (Control) for 36h. Immunofluorescence analysis was performed using an anti-Flag antibody (red)

Cell-cell fusion was measured and expressed as percentage relative to the D614 control (right panel). (C,D) Data represent means±SD of 5 fields from three replicates

SARS-CoV-2 Alpha, Beta, Gamma and Delta spike variants pseudovirus infectivity and syncytia formation in lung cells is inhibited by nitazoxanide

A-D) HEK293T cells transfected with plasmids for production of SARS-CoV-2 Alpha, Beta, Gamma and Delta spike pseudotyped-LUC LV particles, as described in Fig

Error bars indicate means±SD. **P<0.01; Student's t-test. (E-H) HEK293T cells cotransfected with plasmids encoding SARS-CoV-2 Alpha, Beta, Gamma or Delta S variants together with GFP for 4h and treated with NTZ (5 µg/ml) or vehicle (Control) for 36h were overlaid on A549 hACE2 cell monolayers. After 4h, cell-cell fusion was assessed by fluorescence microscopy (left panel)

Financial support for this study was in part provided by Romark Laboratories LC, the company that owns the intellectual property rights related to nitazoxanide. JF Rossignol is an employee and stockholder of Romark Laboratories, LC.

A. Riccio, SS and SP performed the analysis of protein synthesis, maturation and intracellular localization; A. Rossi performed the pseudovirus studies; A. Riccio and SS conducted the cell-cell fusion study; MGS and JFR designed the study; MGS, AR and SS wrote the manuscript. All authors contributed to the interpretation of the data and approve the content of the manuscript.